Dear all,
The ASGO Journal Club presents an insightful session titled "HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma."
The objective of the research team is as follows: uterine carcinosarcoma (UCS) is uncommon high-grade endometrial cancer with limited treatment options. The team evaluated the prognostic significance of human epidermal growth factor receptor 2 (HER2) expression and HER2 gene amplification within large cohorts of UCS, and clarify clinicopathologic characteristics of HER2-low UCS.
Please check below for further details!
